UroGen Pharma Q4 Revenue $37.8M Beats Estimates, Narrows Loss to $0.54
UroGen Pharma posted a $0.54 loss in Q4 2025 vs. $0.66 consensus and $37.84 million revenue, up from $24.57 million a year earlier and 6.4% above forecasts. It recorded $15.8 million of 2025 ZUSDURI sales, secured a permanent J Code in January 2026, refinanced its term loan with Pharmakon Advisors.
1. Q4 2025 Financial Performance
UroGen Pharma reported a $0.54 per-share loss in the fourth quarter of 2025 compared with a consensus loss of $0.66 and a $0.80 loss a year earlier, representing an 18.2% earnings surprise. Revenue reached $37.84 million, up 54% from $24.57 million in Q4 2024 and exceeding estimates by 6.4%.
2. ZUSDURI Commercial Launch and Reimbursement
The company generated $15.8 million in net sales of ZUSDURI during 2025 following its full commercial launch. A permanent J Code effective January 1, 2026 will simplify billing and enhance patient access through standardized reimbursement procedures.
3. Refinancing with Pharmakon Advisors
UroGen completed a refinancing of its term loan with Pharmakon Advisors, securing additional non-dilutive capital on improved terms. The deal strengthens the balance sheet and extends the company’s cash runway for ongoing clinical and commercial activities.